Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered immune cells take on tough T-Cell cancers

NCT ID NCT06316427

First seen Dec 02, 2025 · Last updated Apr 30, 2026 · Updated 19 times

Summary

This study tests a new treatment using specially engineered immune cells (CD7 CAR T-cells) for people with T-cell cancers that have come back or not responded to standard therapy. The cells are made from the patient's own blood or from a donor. The goal is to check safety first, then see how well the treatment shrinks or eliminates the cancer. About 80 participants will be enrolled across multiple hospitals.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing GoBroad Hospital

    RECRUITING

    Beijing, Beijing Municipality, 102206, China

  • Shanghai Liquan Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 201418, China

  • The General Hospital of Western Theater Command PLA

    NOT_YET_RECRUITING

    Chengdu, Sichuan, 610083, China

  • Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200435, China

Conditions

Explore the condition pages connected to this study.